PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16781005-3 2006 Therefore, we conducted a prospective feasibility study designed specifically to evaluate the efficacy of carboplatin (day 1) and irinotecan (days 1, 8, 15) with granulocyte colony-stimulating factor (G-CSF) support in elderly SCLC patients. Irinotecan 130-140 colony stimulating factor 3 Homo sapiens 162-199 28011495-8 2017 Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l. Irinotecan 168-178 colony stimulating factor 3 Homo sapiens 0-37 28011495-8 2017 Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l. Irinotecan 168-178 colony stimulating factor 3 Homo sapiens 39-44 22415148-1 2012 PURPOSE: We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination. Irinotecan 41-51 colony stimulating factor 3 Homo sapiens 169-206 22415148-1 2012 PURPOSE: We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination. Irinotecan 53-59 colony stimulating factor 3 Homo sapiens 169-206 16781005-3 2006 Therefore, we conducted a prospective feasibility study designed specifically to evaluate the efficacy of carboplatin (day 1) and irinotecan (days 1, 8, 15) with granulocyte colony-stimulating factor (G-CSF) support in elderly SCLC patients. Irinotecan 130-140 colony stimulating factor 3 Homo sapiens 201-206 15292935-0 2004 Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Irinotecan 20-30 colony stimulating factor 3 Homo sapiens 87-124 16020968-13 2005 CONCLUSIONS: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. Irinotecan 26-32 colony stimulating factor 3 Homo sapiens 38-43 11822765-6 2001 When G-CSF was added, dose escalation beyond 350 mg/m2 could not be achieved due to grade 2-3 toxicities that prevented on-time retreatment with CPT-11. Irinotecan 145-151 colony stimulating factor 3 Homo sapiens 5-10 11822765-11 2001 CONCLUSIONS: When administered every two weeks, the recommended phase II starting dose of CPT-11 is 250 mg/m2 when given alone and 300 mg/m2 when supported by G-CSF. Irinotecan 90-96 colony stimulating factor 3 Homo sapiens 159-164 11137204-7 2000 RESULTS: At the dose of CPT-11 120 mg/m2, three out of four enrolled patients presented DLTs (grade 4 neutropenia, febrile neutropenia and delayed diarrhea); the addition of G-CSF at this level did not permit further dose-escalation. Irinotecan 24-30 colony stimulating factor 3 Homo sapiens 174-179 11142689-0 2000 Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer. Irinotecan 44-54 colony stimulating factor 3 Homo sapiens 78-115 11142689-1 2000 A phase I study was conducted in patients with stage IIIB or IV non-small cell lung cancer to determine the maximum tolerated dose (MTD) of irinotecan combined with a fixed schedule of docetaxel and carboplatin with recombinant human granulocyte colony stimulating factor (rhG-CSF) (nartograstim) support. Irinotecan 140-150 colony stimulating factor 3 Homo sapiens 234-271 10321506-0 1999 A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Irinotecan 20-30 colony stimulating factor 3 Homo sapiens 79-116 10410150-1 1999 Two phase I studies (CIC-therapy) were conducted in advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerable dose (MTD) of CPT-11 combined with cisplatin and ifosfamide, and MTD of cisplatin combined with CPT-11 and ifosfamide with G-CSF support, respectively. Irinotecan 145-151 colony stimulating factor 3 Homo sapiens 254-259 7521905-0 1994 Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. Irinotecan 35-45 colony stimulating factor 3 Homo sapiens 83-120 9155540-0 1997 A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Irinotecan 19-29 colony stimulating factor 3 Homo sapiens 78-115 9155540-1 1997 We conducted a phase I study to examine whether support with recombinant human granulocyte colony-stimulating factor (rG-CSF) would permit dose intensification of irinotecan (CPT-11) in combination with cisplatin (20 mg/m2 x 5 days) in non-small cell lung cancer (NSCLC) patients. Irinotecan 163-173 colony stimulating factor 3 Homo sapiens 79-116 9155540-1 1997 We conducted a phase I study to examine whether support with recombinant human granulocyte colony-stimulating factor (rG-CSF) would permit dose intensification of irinotecan (CPT-11) in combination with cisplatin (20 mg/m2 x 5 days) in non-small cell lung cancer (NSCLC) patients. Irinotecan 175-181 colony stimulating factor 3 Homo sapiens 79-116 8841050-16 1996 In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma. Irinotecan 72-78 colony stimulating factor 3 Homo sapiens 206-211 8841050-16 1996 In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma. Irinotecan 89-95 colony stimulating factor 3 Homo sapiens 206-211 8683231-2 1996 MATERIALS AND METHODS: The recommended phase II dose of weekly CPT-11 administered as a 90-minute infusion is 145 mg/m2 with granulocyte colony-stimulating factor (G-CSF) and maximal antidiarrheal support. Irinotecan 63-69 colony stimulating factor 3 Homo sapiens 125-162 8683231-2 1996 MATERIALS AND METHODS: The recommended phase II dose of weekly CPT-11 administered as a 90-minute infusion is 145 mg/m2 with granulocyte colony-stimulating factor (G-CSF) and maximal antidiarrheal support. Irinotecan 63-69 colony stimulating factor 3 Homo sapiens 164-169 7505810-0 1994 Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Irinotecan 17-27 colony stimulating factor 3 Homo sapiens 47-84 35354375-8 2022 G-CSF use was observed among 63.6%, 34.9%, 33.9%, and 44.9% of patients treated with FOLFIRINOX, FOLFOX, FOLFIRI, and liposomal irinotecan-based regimens, respectively. Irinotecan 128-138 colony stimulating factor 3 Homo sapiens 0-5